Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of velcade (PS-341/Bortezomib) cytotoxicity in myeloma cell lines

Terry H Landowski, Christina J. Megli, Kevin D. Nullmeyer, Ron Lynch, Robert T Dorr

Research output: Contribution to journalArticle

166 Citations (Scopus)

Abstract

The proteasome inhibitor bortezomib (also known as Ps-341/Velcade) is a dipeptidyl boronic acid that has recently been approved for use in patients with multiple myeloma. Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of cytotoxicity is not well understood. In this report, oligonucleotide microarray analysis of the 8226 multiple myeloma cell line showed a predominant induction of gene products associated with the endoplasmic reticulum secretory pathway following short-term, high-dose exposure to bortezomib. Examination of mediators of endoplasmic reticulum stress-induced cell death showed specific activation of caspase 12, as well as of caspases 8, 9, 7, and 3, and cleavage of bid. Treatment of myeloma cells with bortezomib also showed disregulation of intracellular Ca2+ as a mechanism of caspase activation. Cotreatment with a panel of Ca2+-modulating agents identified the mitochondrial uniporter as a critical regulatory factor in bortezomib cytotoxicity. The uniporter inhibitors ruthenium red and Ru360 prevented caspase activation and bid cleavage, and almost entirely inhibited bortezomib-induced cell death, but had no effect on any other chemotherapeutic drug examined. Additional Ca 2+-modulating agents, including 2-amino-ethoxydiphenylborate, 1,2-bis (o-aminophenoxy) ethane-tretraacetic acid (acetoxymethyl) ester, and dantrolene, did not alter bortezomib cytotoxicity. Analysis of intracellular Ca2+ showed that the ruthenium-containing compounds inhibited Ca 2+ store loading and abrogated the desensitized capacitative calcium influx associated with bortezomib treatment. These data support the hypothesis that intracellular Ca2+ disregulation is a critical determinant of bortezomib cytotoxicity.

Original languageEnglish (US)
Pages (from-to)3828-3836
Number of pages9
JournalCancer Research
Volume65
Issue number9
DOIs
StatePublished - May 1 2005

Fingerprint

Cell Line
Cell Death
Caspases
Multiple Myeloma
Ruthenium Compounds
Caspase 12
Bortezomib
Boronic Acids
Dantrolene
Ruthenium Red
Proteasome Inhibitors
Endoplasmic Reticulum Stress
Ethane
Caspase 9
Caspase 8
Secretory Pathway
Microarray Analysis
Oligonucleotide Array Sequence Analysis
Endoplasmic Reticulum
Esters

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of velcade (PS-341/Bortezomib) cytotoxicity in myeloma cell lines. / Landowski, Terry H; Megli, Christina J.; Nullmeyer, Kevin D.; Lynch, Ron; Dorr, Robert T.

In: Cancer Research, Vol. 65, No. 9, 01.05.2005, p. 3828-3836.

Research output: Contribution to journalArticle

@article{25a7f353d5c1492482d08ff44125d89c,
title = "Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of velcade (PS-341/Bortezomib) cytotoxicity in myeloma cell lines",
abstract = "The proteasome inhibitor bortezomib (also known as Ps-341/Velcade) is a dipeptidyl boronic acid that has recently been approved for use in patients with multiple myeloma. Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of cytotoxicity is not well understood. In this report, oligonucleotide microarray analysis of the 8226 multiple myeloma cell line showed a predominant induction of gene products associated with the endoplasmic reticulum secretory pathway following short-term, high-dose exposure to bortezomib. Examination of mediators of endoplasmic reticulum stress-induced cell death showed specific activation of caspase 12, as well as of caspases 8, 9, 7, and 3, and cleavage of bid. Treatment of myeloma cells with bortezomib also showed disregulation of intracellular Ca2+ as a mechanism of caspase activation. Cotreatment with a panel of Ca2+-modulating agents identified the mitochondrial uniporter as a critical regulatory factor in bortezomib cytotoxicity. The uniporter inhibitors ruthenium red and Ru360 prevented caspase activation and bid cleavage, and almost entirely inhibited bortezomib-induced cell death, but had no effect on any other chemotherapeutic drug examined. Additional Ca 2+-modulating agents, including 2-amino-ethoxydiphenylborate, 1,2-bis (o-aminophenoxy) ethane-tretraacetic acid (acetoxymethyl) ester, and dantrolene, did not alter bortezomib cytotoxicity. Analysis of intracellular Ca2+ showed that the ruthenium-containing compounds inhibited Ca 2+ store loading and abrogated the desensitized capacitative calcium influx associated with bortezomib treatment. These data support the hypothesis that intracellular Ca2+ disregulation is a critical determinant of bortezomib cytotoxicity.",
author = "Landowski, {Terry H} and Megli, {Christina J.} and Nullmeyer, {Kevin D.} and Ron Lynch and Dorr, {Robert T}",
year = "2005",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-04-3684",
language = "English (US)",
volume = "65",
pages = "3828--3836",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of velcade (PS-341/Bortezomib) cytotoxicity in myeloma cell lines

AU - Landowski, Terry H

AU - Megli, Christina J.

AU - Nullmeyer, Kevin D.

AU - Lynch, Ron

AU - Dorr, Robert T

PY - 2005/5/1

Y1 - 2005/5/1

N2 - The proteasome inhibitor bortezomib (also known as Ps-341/Velcade) is a dipeptidyl boronic acid that has recently been approved for use in patients with multiple myeloma. Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of cytotoxicity is not well understood. In this report, oligonucleotide microarray analysis of the 8226 multiple myeloma cell line showed a predominant induction of gene products associated with the endoplasmic reticulum secretory pathway following short-term, high-dose exposure to bortezomib. Examination of mediators of endoplasmic reticulum stress-induced cell death showed specific activation of caspase 12, as well as of caspases 8, 9, 7, and 3, and cleavage of bid. Treatment of myeloma cells with bortezomib also showed disregulation of intracellular Ca2+ as a mechanism of caspase activation. Cotreatment with a panel of Ca2+-modulating agents identified the mitochondrial uniporter as a critical regulatory factor in bortezomib cytotoxicity. The uniporter inhibitors ruthenium red and Ru360 prevented caspase activation and bid cleavage, and almost entirely inhibited bortezomib-induced cell death, but had no effect on any other chemotherapeutic drug examined. Additional Ca 2+-modulating agents, including 2-amino-ethoxydiphenylborate, 1,2-bis (o-aminophenoxy) ethane-tretraacetic acid (acetoxymethyl) ester, and dantrolene, did not alter bortezomib cytotoxicity. Analysis of intracellular Ca2+ showed that the ruthenium-containing compounds inhibited Ca 2+ store loading and abrogated the desensitized capacitative calcium influx associated with bortezomib treatment. These data support the hypothesis that intracellular Ca2+ disregulation is a critical determinant of bortezomib cytotoxicity.

AB - The proteasome inhibitor bortezomib (also known as Ps-341/Velcade) is a dipeptidyl boronic acid that has recently been approved for use in patients with multiple myeloma. Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of cytotoxicity is not well understood. In this report, oligonucleotide microarray analysis of the 8226 multiple myeloma cell line showed a predominant induction of gene products associated with the endoplasmic reticulum secretory pathway following short-term, high-dose exposure to bortezomib. Examination of mediators of endoplasmic reticulum stress-induced cell death showed specific activation of caspase 12, as well as of caspases 8, 9, 7, and 3, and cleavage of bid. Treatment of myeloma cells with bortezomib also showed disregulation of intracellular Ca2+ as a mechanism of caspase activation. Cotreatment with a panel of Ca2+-modulating agents identified the mitochondrial uniporter as a critical regulatory factor in bortezomib cytotoxicity. The uniporter inhibitors ruthenium red and Ru360 prevented caspase activation and bid cleavage, and almost entirely inhibited bortezomib-induced cell death, but had no effect on any other chemotherapeutic drug examined. Additional Ca 2+-modulating agents, including 2-amino-ethoxydiphenylborate, 1,2-bis (o-aminophenoxy) ethane-tretraacetic acid (acetoxymethyl) ester, and dantrolene, did not alter bortezomib cytotoxicity. Analysis of intracellular Ca2+ showed that the ruthenium-containing compounds inhibited Ca 2+ store loading and abrogated the desensitized capacitative calcium influx associated with bortezomib treatment. These data support the hypothesis that intracellular Ca2+ disregulation is a critical determinant of bortezomib cytotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=18144431710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144431710&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-3684

DO - 10.1158/0008-5472.CAN-04-3684

M3 - Article

C2 - 15867381

AN - SCOPUS:18144431710

VL - 65

SP - 3828

EP - 3836

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 9

ER -